Previous reports have suggested that the protooncogene c-myb participates in T cell development in the thymus and mature T cell proliferation. We have generated two T cell-specific c-myb knockout mouse models, myb͞LckCre and myb͞CD4Cre. We have demonstrated that c-myb is required for the development of thymocytes at the DN3 stage, for survival and proliferation of double-positive thymocytes, for differentiation of single-positive CD4 and CD8 T cells, and for the proliferative responses of mature T cells. In addition, our data show that c-myb is directly involved in the formation of double-positive CD4؉CD8؉CD25؉, CD4؉CD25؉, and CD8؉CD25؉ T cells, developmental processes that may imply a role for c-myb in autoimmune dysfunction.
T
he process of thymocyte development involves tightly regulated steps of progressive cellular differentiation, selection, and lineage commitment (1) . The most immature double-negative (DN) CD4ϪCD8Ϫ thymocytes develop into double-positive (DP) CD4ϩCD8ϩ thymocytes, which give rise to immature singlepositive (SP) CD4ϩ or SP CD8ϩ T cells. The DN population can be further subdivided into progressive levels of maturity: CD44ϩCD25Ϫ (DN1), CD44ϩCD25ϩ (DN2), CD44-CD25ϩ (DN3), and CD44-CD25Ϫ (DN4). Progression beyond the DN3 stage depends on the successful rearrangement of a T cell antigen receptor (TCR)␤ gene and preTCR signaling, whereas differentiation from DP to mature SP cell depends on the expression and positive selection of TCR␣␤.
The nuclear protooncogene c-myb, which belongs to the myb family of transcription factors, is believed to be an important regulator of cell growth, survival, and differentiation during hematopoiesis (2) . c-myb is expressed predominately in hematopoietic tissues and is crucial for fetal hepatic erythropoiesis, because homozygous c-myb null mice die in utero of severe anemia at embryonic day 15 (3) . Using c-myb-null͞rag-deficient blastocyst chimeric mice, it was found that c-myb is critical for maturation to the DN1 stage of thymopoiesis (4) . Furthermore, by using a knock-down mouse model, it was shown that this gene is required at a high threshold for progression beyond the DN2 stage (5) . In addition, transgenic expression of a dominant interfering c-Myb was found to result in the accumulation of cells at the DN3 stage of T cell development and impairment of mature T cell proliferation (6) . Because constitutive loss of c-myb gene leads to embryonic lethality, and because there could be nonspecific inhibition by the dominant interfering c-Myb, it has not been possible to accurately assess the role of this gene in adult T cell development and mature T cell function. Therefore, to define the role of c-myb in T cell development and mature T cell function, we have generated two T cell-specific c-myb knockout mouse models, myb F/F ͞LckCre and myb F/F ͞CD4Cre, which delete c-myb at two specific stages of T cell development. Results presented in this report show that c-myb is essential for the development of thymocytes at the DN3 stage, for survival and proliferation of DP thymocytes, for differentiation of SP CD4 and SP CD8 T cells, and for the proper proliferative responses of mature T cells. In addition, our data indicate that c-myb is directly involved in the formation of cells expressing CD25 at both the DP and SP stages. The development of CD25ϩ T cells may implicate c-myb in autoimmune dysfunction.
Methods
Generation of Floxed c-myb Mice. We isolated a BamHI genomic clone of c-myb encoding exons 2-8 (7), to produce a gene-targeting vector, pCMTSK2 (Fig. 1a) . A 0.9-kb fragment containing exon 6 was generated by PCR amplification and cloned into the BamHI site of the pflox vector (8, 9) . The flanking 6.0-kb fragment on the 5Ј end containing exons 2-5 and the flanking 2.5-kb fragment on the 3Ј end containing exons 7 and 8 were generated by a combination of PCR and restriction enzyme digestion and cloned into the SalI and XhoI sites, respectively. Then the backbone of pCMTSK was modified to contain a BamHI site in place of the NheI site. After the construction of pCMTSK2, the entire clone was sequenced to ascertain that PCR technique did not produce any mutations or deletions.
NotI-linearized pCMTSK2 was introduced into mouse R1 embryonic stem (ES) cells via electroporation. ES cells were cultured and selected as described (9) . Genomic DNA from neomycinresistant ES cells was digested with BamHI, and homologous recombinants were identified by Southern blotting by using a c-myb-specific probe upstream of exon 2 (probe A). Homologous recombinants revealed two bands: 11.5 (wild-type) and 9.8 kb (recombinant). To remove the PGKneo R -thymidine kinase marker, recombinant ES cell clones were subjected to transient expression of Cre recombinase by electroporation of pPGKcre-bpA and subsequent selection in the presence of ganciclovir (9) . DNA from subclones resistant to ganciclovir were isolated, digested with BamHI, and analyzed by Southern blotting by using probe A to identify floxed and knockout alleles as 8.5 and 10.5 kb, respectively. Three myb F/ϩ ES clones were injected into C57BL͞6 ϫ DBA2 blastocysts by the University of Michigan Transgenic Core Facility, and chimeric male mice were crossed to C57BL͞6 mice to generate two heterozygous mouse lines for the myb F allele. Both the LckCre and CD4cre transgenes were genotyped, as described on www.jax. org for LckCre transgenic mice.
according to the manufacturer's protocol (BD Biosciences). For cell sorting, single-cell suspensions were labeled and sorted on a highspeed cell sorter (MoFlo; DakoCytomation, Carpenteria, CA) to a purity of Ͼ95% at the Wistar Institute, Philadelphia. For cell cycle analysis, sorted cells were stained with DRAQ5 according to the manufacturer's instructions (Biostatus Limited, Leicestershire, U.K.). For Western analysis, 100 g of protein extract was run on a 10% SDS-polyacrylamide gel and transferred to nitrocellulose for immunoblotting. Antibodies for c-Myb (Upstate Biotechnology, Lake Placid, NY), Proliferating Cell Nuclear Antigens, Cdk1͞Cdc2 (Santa Cruz Biotechnology), and ␤-actin (Sigma) were used to probe the membranes. Statistical Analysis. Data are expressed as means Ϯ standard deviations. Comparisons were analyzed by using Student's twopaired t test with the same variance. Differences were considered significant when P Ͻ 0.05.
Results
Generating Floxed c-myb Mutant Mice. To circumvent the embryonic lethality associated with c-myb nullizygosity, we used the Cre-LoxP recombination system to achieve tissue-specific deletion of c-myb (8, 9) . We flanked exon 6 of c-myb, which encodes a high-affinity DNA-binding domain, with loxP sites (Fig. 1a) . The neomycin and thymidine kinase markers were removed by transient expression of Cre recombinase in four recombinant ES cell clones. Three clones with deletion of the markers but retention of loxP sites around exon 6 were injected into blastocysts, and germ-line transmission of the floxed c-myb allele was obtained for two of the three clones. The myb F/F homozygotes had normal behavior, appearance, and development and followed a Mendelian distribution, indicating that the myb F allele is fully functional. In addition, there are no differences in the abundance of RNA and protein in the bone marrow, spleen, and thymus from the three genotypic groups (data not shown). Intercrosses between myb ϩ/KO mice generated no myb KO/KO mice in Ͼ150 births. (Fig. 3a) . Analysis of the subsets of DN thymocytes by surface staining for CD44 and CD25 showed an accumulation of thymocytes at the DN3 stage of early T cell development ( Fig. 2 a  and b) . The accumulation of thymocytes at the DN3 stage may impede cells from progressing into the DN4 stage, which may account for the significant decrease in thymocytes at the DN4 stage in the mutant mice compared with LMC. The mutant DN cells exhibit decreased surface staining for TCR␤ ( Fig. 2 c and d) , suggesting a defect in the TCR␤ rearrangement process itself or a step before ␤ rearrangement. Further analysis (Fig. 2 c and d) shows there is no significant difference in the percentage of ␥␦ thymocytes within the total DN population in the mutant mice as compared with LMC, indicating that c-myb may not have a role in the development of the ␥␦ population in these mutant mice.
Requirement of c-myb at the DP Stage of Thymocyte Development. In the myb F/F ͞LckCre mouse model, the percentage of DP population is reduced to 62% (range, 43-84%) of total thymocytes (Fig. 3a) . Despite a reduction in the percentage of DP thymocytes, it is difficult to ascertain the exact contribution of c-myb to the DP stage in the c-myb F/F ͞LckCre model, because the DN stage is altered and there is a 100-fold expansion going from the DN to the DP stage. Therefore, we generated the myb F/F ͞CD4Cre mouse model, which is first active at the DP stage, to facilitate the study of the DP thymocyte population (11) . Like the myb F/F ͞LckCre mouse model, the thymic cellularity of the myb F/F ͞CD4Cre is also reduced, but by a modest 17% (Fig. 3a) . The percentages of DP thymocytes in the myb F/F ͞CD4Cre mice and their LMC are similar (Fig. 3a) . However, the absolute value of the myb F/F ͞CD4Cre DP thymocytes (114 ϫ 10 6 vs. 136 ϫ 10 6 in LMC) is reduced by 17%, indicating a requirement of c-myb at the DP stage for fully normal thymocyte development.
Development of DP CD25؉ Thymocytes in the Absence of c-myb.
Closer examination of the DP thymocytes from the myb F/F ͞ CD4Cre mutant mice revealed that Ϸ37% (range, 19-48%) of the DP thymocytes express CD25, the IL-2R␣ chain, as compared with Ͻ3% in LMC (Fig. 3 a and d) . This very dramatic alteration in T cell development was also observed in the DP cells of the myb F/F ͞LckCre mice (Fig. 3 a and d ), albeit at a higher percentage (i.e., 53% compared with Ͻ2% in LMC). The DP CD25ϩ thymocyte population did not express CD122, the IL-2R␤ chain, suggesting that these mutant cells express only the low-affinity IL-2R on their surface (data not shown). To define the DP CD25ϩ population, we sorted the DP CD25ϩ and the DP CD25Ϫ thymocyte populations from mutant myb F/F ͞ CD4Cre mice and DP cells from LMC and examined c-Myb protein expression (Fig. 1c) . The mutant DP CD25ϩ had no detectable c-Myb protein expression, which correlates with DNA data that showed complete absence of the floxed c-myb allele in the mutant DP CD25ϩ thymocyte population, indicating that the full deletion of c-myb favors the development of DP CD25ϩ cells (Fig. 1b) . On the contrary, the DP CD25Ϫ thymocyte population from the mutant mice had a decreased level of c-Myb protein expression, which is consistent with the partial deletion of the floxed c-myb allele ( Fig. 1 b and c) . Because the efficiency of Cre-mediated deletion of floxed c-myb in the DP thymocyte population is similar in both the mutant mouse models (Fig. 1b) , this indicates that the dramatic decrease in the thymic cellularity seen in the myb F/F ͞LckCre is mainly due to events that occur during the DN stage of T cell development and not at the DP stage.
Deficient Proliferative and Survival Capacity of Mutant DP CD25؉
Thymocytes. Because c-myb is implicated in proliferation in many systems, we wished to determine the proliferative activity of the unusual DP CD25ϩ population from the myb F/F ͞CD4Cre mice by measuring [ 3 H]-thymidine incorporation (Fig. 4c) . The mutant DP CD25ϩ thymocyte population displayed greatly impaired [ 3 H]-thymidine uptake, exhibiting only 15% uptake compared with that of DP cells from LMC. The reduced [ 3 H]-thymidine uptake in the mutant DP CD25ϩ thymocyte population is consistent with the reduced percentage of these cells in S and G 2 ͞M phases of the cell cycle when compared with DP cells from LMC (Fig. 4a) . In contrast, the mutant DP CD25Ϫ thymocyte population has nearly 2-fold greater [ 3 H]-thymidine uptake when compared with that of DP cells from LMC, suggesting that these cells may be compensating for the absence of c-Myb. This greater [ 3 H]-thymidine uptake seen in the mutant DP cells is consistent with cell cycle data, which indicate an increased percentage of this population in the S and G 2 ͞M phases of the cell cycle as compared with DP cells from LMC (Fig. 4a) . We performed RNase protection analysis (RPA) using RNA from mutant DP CD25ϩ, mutant DP CD25Ϫ, and wild-type DP thymocyte populations and found no difference in the levels of cdk2, cyclin E, c-myc, max, bcl-w, bfl-1, bak, bax, bcl-2, bad, bcl-x, NFk〉, fas, PARP, caspase3, p53, p21, and p27 among the three thymocyte populations (data not shown). However, we observed a decrease in RNA abundance of cdk1 and proliferating cell nuclear antigens (PCNA) in the mutant DP CD25ϩ population but not in the other two populations (data not shown). Consistent with our RPA data, Western blot analysis indicates that the abundance of Cdk1, a known c-Myb target gene, and PCNA proteins are reduced in the mutant DP CD25ϩ (Fig. 4b) , consistent with an impairment in the proliferative capacity of DP CD25ϩ thymocytes (12) .
Because survival is another of the described functions of c-Myb in hematopoietic cells, we sorted mutant DP CD25ϩ, mutant DP CD25Ϫ, and control DP cells and assessed cellular survival over 18 h by annexin V staining (Fig. 4d) . Under these conditions, there was no difference in survival between the mutant DP CD25Ϫ cells or the DP cells from LMC. In contrast, the mutant DP CD25ϩ population lost viability more rapidly than either the mutant DP CD25Ϫ cells or the DP cells from LMC, suggesting that c-Myb provides a survival signal(s) to DP cells.
Requirement of c-myb at the SP Stage of T Cell Development.
We observed a decrease in the percentage of SP CD4 T cells that is reflected in the altered ratio of CD4 to CD8 T cells in the thymi of the myb F/F ͞CD4Cre mice (1.3 vs. 3.0 in LMC) (Fig. 3a) . The decrease in the percentage of the thymic SP CD4 T cells leads to a decrease in the percentage of mature CD4 T cells, in the ratio of CD4 to CD8 T cells, and in the ratio of CD4 T cells to B220, a pan-B cell marker, in both the spleen and the lymph nodes of both the mutant mouse models when compared with their respective LMC ( Fig. 3a and Table 1 ). This suggests that c-myb has a role in the differentiation of the CD4 T cells. In contrast, we observed an increase in the percentage of thymic SP CD8 T cells of the myb F/F ͞CD4Cre mice. This observation suggests either that the deletion of c-myb directly accelerates the differentiation of SP CD8 T cells or that the impaired differentiation of SP CD4 T cells enhances the formation of SP CD8 T cells (Fig. 3a and Table 1 ). However, there is no change in the percentage of CD8 T cells in either the spleen or lymph nodes of the myb F/F ͞CD4Cre mice when compared with LMC (Table 1) .
Increased Presence of Immature and Mature CD4 CD25؉ and CD8
CD25؉ in the Mutant Mouse Models. In both the myb F/F ͞CD4Cre and myb F/F ͞LckCre mouse models, we detected a slight but con- (Fig. 3a and data not shown). We observed that this increase in thymic SP CD4 CD25ϩ cells results in a slight but significant percentage increase in the mature CD4 CD25ϩ T cells in the lymph nodes of the myb F/F ͞CD4Cre mice and in both the spleen and lymph nodes of the myb F/F ͞LckCre mice. We also found that there are 2-and 13-fold increases in thymic CD3 hi SP CD8 CD25ϩ cells in the myb F/F ͞CD4Cre and myb F/F ͞LckCre mice, respectively. This increase in thymic SP CD8 CD25ϩ translates into a slight percentage increase of peripheral CD8 CD25ϩ T cells in both the spleen and lymph nodes of the myb F/F ͞CD4Cre mice. Similarly, the 13-fold increase in the SP CD8 CD25ϩ thymocytes of the myb F/F ͞LckCre mice accounts for a 3-fold increase in mature CD8 CD25ϩ T cells in the spleen and lymph nodes. Our data suggest that formation of these mutant CD4 CD25ϩ and CD8 CD25ϩ immature and mature T cells is due to altered events at the DP stage as a consequence of depleted abundance of c-Myb.
Requirement of c-myb for Proper Proliferative Response of Mature T
Cells to Mitogens. We next tested the proliferative response of purified splenic CD4 and CD8 T cells from myb F/F ͞CD4Cre mice to stimulation by either anti-CD3͞anti-CD28, IL-2, PHA, or PMA (Fig. 5a ). Results show that purified splenic CD4 T cells from mutant mice have an Ϸ50% lower response as measured by [ 3 H]-thymidine uptake after stimulation with either anti-CD3͞anti-CD28, PHA, or PMA. However, there was no difference in the response to IL-2 when compared with LMC, which is in contrast to previously published data (13, 14) . In contrast, purified splenic CD8 T cells show a 3-fold greater response to either anti-CD3͞anti-CD28 or IL-2, but not PHA or PMA (Fig. 5a) . These results are consistent with data showing a 6-fold increase in IFN␥ secretion by the mutant CD8 T cells in response to anti-CD3͞anti-CD28 (Fig. 5b) .
Discussion
We have created two T cell-specific c-myb knockout mouse models, myb F/F ͞CD4Cre and myb F/F ͞LckCre mice, by using the Cre-Lox recombination system, which enabled us to examine various stages of T cell development as well as mature T cell function. We observed an accumulation of thymocytes at the DN3 stage that indicates an important role for c-myb at this point in early T cell development. While this manuscript was in preparation, we became aware of a report by Bender et al. (15) showing that c-myb is essential at the DN3 stage of T cell development. Although
Bender's group and we arrived at the same conclusion, the accumulation of thymocytes at the DN3 stage is less striking in our model. This probably reflects the different efficiencies of Cremediated deletion of the floxed c-myb in our LckCre (10) mice vs. the cwLckCre (11) mice used by Bender et al. (15) . However, at odds with this report, we detected no significant difference in the percentage of the ␥␦ population as a total of the DN population in the myb F/F ͞LckCre mice compared with LMC. The disparate results may reflect the different Cre mice used and the different efficiencies of Cre-mediated deletion of floxed c-myb in the DN stage.
Our data from the myb F/F ͞CD4Cre mouse model indicate that there is a requirement for c-myb in DP thymocyte development. Our data suggest that the function of c-myb in these cells is to confer both proliferative and survival capabilities. When c-Myb is lost in DP thymocytes, the proliferative and survival capacities of these cells are impaired, and this is associated with the expression of CD25. We do not believe that CD25 is a bona fide c-Myb target gene, at least at the DP stage. For instance, in the mutant DP CD25Ϫ cells where floxed c-myb allele is partially deleted, CD25 is not expressed. We therefore believe that the expression of CD25 by the c-Myb-deficient DP thymocytes serves only as a marker of defective cells that need to be eliminated from the thymic environment. Consistent with this notion, addition of IL-2 has no effect on 3 H-thymidine uptake or apoptosis in the mutant DP CD25ϩ thymocytes (data not shown). Furthermore, our interpretation is consistent with the phenotype of IL-2-deficient mice that develop various forms of autoimmunity, because autoreactive T cells are not deleted to provide central tolerance (16, 17) . Interestingly, it has been reported that DP thymocytes treated with anti-CD3 to induce cell death down-regulate CD4 and CD8 but up-regulate TCR␤, CD3, CD69, and CD25 (18) . Although c-myb-deficient DP CD25ϩ cells do not down-regulate CD4 and CD8 and are CD69 Ϫ , CD3 lo , and TCR␤ lo (data not shown), expression of CD25 on DP thymocytes may be indicative of defective cells that would normally be purged from the thymic environment.
In the mutant DP CD25Ϫ thymocytes, there is nearly twice the proliferative index of the DP thymocytes of LMC. Because our mice are c-Myb depletion models and the half-life of c-Myb protein is Ϸ60 min (19), we believe that virtually all of the remaining c-Myb protein in the DP CD25Ϫ thymocytes (Fig. 1c) comes from the undeleted floxed c-myb allele (Fig. 1b) . We believe that the mutant cells have compensated for the absence of c-Myb by using a c-Myb-independent mechanism for proliferation, which is also A-Myb independent because there are no changes in the levels of A-Myb in mutant DP CD25ϩ, DP CD25Ϫ, and DP of LMC (data not shown). Because the mutant DP CD25Ϫ thymocytes can compensate for the proliferative capacity as well as the survival capacity in the absence of c-Myb, these cells are able to progress to the SP stage. Consistent with this interpretation, we observed the presence of SP thymocytes with a partially deleted c-myb allele in the thymi of both c-myb mutant mouse models.
Our data suggest that c-myb is also required in the differentiation of CD4 SP T cells, which is consistent with the study by Bender et al. (15) . Interestingly, we noticed that only Ϸ50% of the floxed c-myb alleles is deleted in the purified splenic CD4 T cells, whereas a near-complete deletion of our floxed c-myb alleles is seen in the SP CD4 T cells in the thymus unlike Bender et al. (15) . This observation suggests that the c-Myb-deficient SP CD4 T cells have a slower maturation rate at the SP stage, a defect in their ability to home to the spleen, and a shorter life span in the periphery and͞or compete poorly for the available niches in the spleen than c-Mybsufficient CD4 T cells. Further experiments should clarify these possibilities.
We observed an increase in the percentage of SP CD8 in our myb F/F ͞CD4Cre mouse model, suggesting that c-myb is required for the differentiation of SP CD8 T cells, which is at odds with the report of Bender et al. (15) . The reason for this discrepancy may lie in the myb͞Cre models used. There appears to be a correlation between the degree of perturbation to the DN stage as measured by the accumulation of thymocytes in the DN stage and in the DN3 stage and the increase in the SP CD8 thymocyte subset. For instance, among the four myb͞Cre models used in our study and that of Bender et al. (15) , the perturbation to the DN stage in order of greatest to least is as follows: Bender's myb f/f ͞cwLckCre, our myb F/F ͞LckCre, Bender's myb f/f ͞LckCre, and our myb F/F ͞CD4Cre mice. In the myb F/F ͞CD4Cre mouse model, no accumulation of cells at the DN3 stage was observed (data not shown). If we now compare the absolute number of SP CD8 thymocytes as a percentage of LMC, the results for the four mouse models in the same order as above are as follow: 12% (6 ϫ 10 in LMC), respectively. Because the myb F/F ͞CD4Cre mouse model has the least perturbation to the DN stage and because events at the DN stage do influence the DP compartment, we believe that the myb F/F ͞CD4Cre mouse model is the model that best portrays the events at the DP and SP stages of T cell development.
Previous attempts to study the role of c-Myb in the function of mature T cells have mainly used antisense oligonucleotides or a dominant interfering c-Myb protein, which can have nonspecific effects (6, 20, 21) . We determined that purified mutant CD4 T cells have a weaker response to anti-CD3͞anti-CD28, PHA, or PMA. On the contrary, mutant CD8 T cells have a greater proliferative response to anti-CD3͞CD28 and IL-2 that may reflect an altered proliferative mechanism as we have observed in the mutant DP CD25Ϫ thymocytes. Hence, our data indicate that c-myb is required for normal proliferative activity of mature CD4 and CD8 T cells.
Interestingly, in both our models, we observed an increase of SP CD4ϩCD25ϩ, SP CD8ϩCD25ϩ, mature CD4 CD25ϩ, and mature CD4 CD25ϩ T cells. It is not clear whether these mutant cells have suppressor functions. However, it appears that these CD25ϩ T cells may have arisen from the DP CD25ϩ cell population. For instance, there is a positive correlation between DP CD25ϩ and SP CD8ϩCD25ϩ in the myb F/F ͞LckCre mice (data not shown). Interestingly, although we observed that 36% of SP CD8 T cells express CD25 in the thymi of myb F/F ͞LckCre mice, CD8 CD25ϩ T cells represent only Ϸ8% of the splenic CD8 T cells and 9% of lymph node CD8 T cells. This observation may reflect that some of these cells are deleted in the thymi, or these cells migrate slowly to the periphery, have a shorter life span in the periphery, or home to nonlymphoid organs. Further studies should clarify these possibilities.
Conclusion
Our data indicate that c-myb is required for T cell development at the stages depicted in Fig. 6 : DN3, DP, SP CD4, and SP CD8. Because c-myb is required for T cell development and normal proliferative response in the periphery, it will be necessary to decipher whether c-myb has a role not only in autoimmune dysfunction but also in T cell leukemia. If we extrapolated our findings here to T leukemic cells, we would predict that depletion of c-Myb would greatly impair the proliferative and survival capacities of most T leukemic cells similarly to what we observed in the DP CD25ϩ cells. However, the presence of DP CD25Ϫ cells suggests that in some instances, replacement of c-Myb function may occur. This assumption would be consistent with the observation of Venturelli et al. (22) , who have shown that down-regulation of c-myb by antisense oligodeoxynucleotides inhibited DNA synthesis of T leukemic cells in most but not all patients. 
